Claritev (CTEV) Stock Analysis & AI Equity Report
Claritev (CTEV) overview
Claritev (CTEV) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 965m and operating profit of USD 28.8m; the year-end share price was 42.75 USD and market capitalisation was USD 708m. Claritev is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Claritev's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Claritev
Claritev provides technology, data, analytics and services to organizations across the U.S. healthcare system. Its offerings address out-of-network cost management, payment integrity, billing and payment accuracy, and in-network payment and revenue integrity. The company serves healthcare payers, providers and other organizations, using claims experience and data-driven insights to help them assess costs, pricing and payment dynamics.
Generate the Claritev report
Claritev is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Claritev and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Claritev
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.